Heritage Investors Management Corp decreased its position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 6.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 138,452 shares of the biopharmaceutical company’s stock after selling 8,765 shares during the quarter. Heritage Investors Management Corp’s holdings in Bristol Myers Squibb were worth $7,468,000 as of its most recent filing with the SEC.
Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after buying an additional 2,743,759 shares during the period. State Street Corp boosted its stake in shares of Bristol Myers Squibb by 2.0% during the third quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock worth $4,356,445,000 after buying an additional 1,855,238 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Bristol Myers Squibb by 11.5% during the third quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company’s stock worth $818,105,000 after buying an additional 1,873,618 shares during the period. Legal & General Group Plc boosted its stake in shares of Bristol Myers Squibb by 8.4% during the third quarter. Legal & General Group Plc now owns 17,075,743 shares of the biopharmaceutical company’s stock worth $770,116,000 after buying an additional 1,317,199 shares during the period. Finally, Pzena Investment Management LLC boosted its stake in shares of Bristol Myers Squibb by 0.4% during the third quarter. Pzena Investment Management LLC now owns 14,901,604 shares of the biopharmaceutical company’s stock worth $672,062,000 after buying an additional 58,129 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Trending Headlines about Bristol Myers Squibb
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: Bristol Myers Squibb announced a strategic agreement with Anthropic to roll out Claude Enterprise across its global operations, giving more than 30,000 employees access to AI tools aimed at speeding up drug discovery, development, manufacturing, and commercial work. Article: Bristol Myers Squibb Announces Strategic Agreement with Anthropic
- Positive Sentiment: The company said it will unveil new data at ASCO 2026, highlighting the strength of its oncology portfolio and next-generation pipeline, which could reinforce confidence in future cancer-drug growth. Article: Bristol Myers Squibb to Unveil New Data at ASCO 2026
- Neutral Sentiment: Market commentary continues to center on the balance between Bristol Myers Squibb’s pipeline potential and patent-expiration risks, keeping investor sentiment tied to upcoming data readouts and execution. Article: How The Bristol Myers Squibb (BMY) Story Is Shifting Around Pipeline Hopes And Patent Risks
Bristol Myers Squibb Price Performance
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same period last year, the firm earned $1.80 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.31 EPS for the current fiscal year.
Bristol Myers Squibb Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 70.79%.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the stock. Morgan Stanley reiterated an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Bank of America decreased their target price on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Piper Sandler reiterated an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $61.31.
View Our Latest Research Report on BMY
Insider Buying and Selling at Bristol Myers Squibb
In other news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is currently owned by company insiders.
Bristol Myers Squibb Company Profile
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Articles
- Five stocks we like better than Bristol Myers Squibb
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
